Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer

Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group

(2009) Olav Dahl et al.   ACTA ONCOLOGICA

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803

(2009) Monica M. Bertagnolli et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinically important aspects of lymph node assessment in colon cancer

(2009) Frances C. Wright et al.   JOURNAL OF SURGICAL ONCOLOGY

Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?

(2008) A. Berglund et al.   ANNALS OF ONCOLOGY

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status

(2008) Rodrigo Jover et al.   EUROPEAN JOURNAL OF CANCER

Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?

(2008) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY